中国麻风皮肤病杂志 ›› 2021, Vol. 37 ›› Issue (1): 30-31.doi: 10.12144/zgmfskin202101030

• 短篇论著 • 上一篇    下一篇

白介素17A拮抗剂治疗儿童银屑病一例并文献复习

孙勇虎,张福仁   

  1. 山东第一医科大学附属皮肤病医院(山东省皮肤病医院)，山东省皮肤病性病防治研究所，济南，250022
  • 出版日期:2021-01-15 发布日期:2021-01-05
  • 通讯作者: 张福仁, E-mail: zhangfuren@hotmail.com

A child with psoriasis successfully treated with interleukin-17A antagonist and literature review

SUN Yonghu, ZHANG Furen   

  1. Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2021-01-15 Published:2021-01-05
  • Contact: ZHANG Furen, E-mail: zhangfuren@hotmail.com

PDF (PC)

259

摘要： 生物制剂治疗银屑病的方案多针对成人设计，国内尚缺乏对儿童银屑病的治疗报道。本文报道1例经白介素17A拮抗剂成功治疗的6岁儿童银屑病患者，并对目前被批准应用于儿童银屑病临床治疗的生物制剂相关文献进行了总结。

关键词: 儿童银屑病, 生物制剂, 白介素17A

Abstract: Currently, the biological agents for the treatment of psoriasis are mostly designed for adults, and there is a lack of clinical research on the standardized treatment of children's psoriasis. We reported a 6-year-old child with psoriasis who was successfully treated with interleukin-17A antagonist and summarized the current biologic agents approved for the clinical treatment for pediatric psoriasis.

Key words: pediatric psoriasis, biological agents, IL17A